Covid-19: Time for a paradigm change

Rev Med Virol. 2020 Sep;30(5):e2134. doi: 10.1002/rmv.2134. Epub 2020 Jul 3.

Authors

Franco M Buonaguro¹, Paolo A Ascierto¹, Gene D Morse², Luigi Buonaguro¹, Igor Puzanov³, Maria Lina Tornesello¹, Christian Bréchot⁴, Robert C Gallo⁵

Affiliations

¹ Istituto Nazionale Tumori-IRCCS "Fondazione G. Pascale", Naples, Italy.
² Center for Integrated Global Biomedical Sciences, University at Buffalo, The State University of New York, USA.
³ Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
⁴ Global Virus Network, University of South Florida, Tampa, Florida, USA.
⁵ Institute of Human Virology, Baltimore, Maryland, USA.

No abstract available

Publication types

Editorial

MeSH terms

Acute Lung Injury / immunology
Acute Lung Injury / prevention & control*
Acute Lung Injury / virology
Anaphylaxis / immunology
Anaphylaxis / prevention & control*
Anaphylaxis / virology
Antibodies, Monoclonal / therapeutic use*
Antiviral Agents / therapeutic use*
Betacoronavirus / drug effects
Betacoronavirus / immunology
Betacoronavirus / pathogenicity
COVID-19
Complement C5a / antagonists & inhibitors
Complement C5a / genetics
Coronavirus Infections / drug therapy*
Coronavirus Infections / immunology
Coronavirus Infections / virology
Cytokine Release Syndrome / immunology
Cytokine Release Syndrome / prevention & control*
Cytokine Release Syndrome / virology
Cytokines / antagonists & inhibitors
Cytokines / genetics
Cytokines / immunology
Disease Progression
Gene Expression Regulation
Host-Pathogen Interactions / genetics
Host-Pathogen Interactions / immunology
Humans
Lymphocytes / drug effects
Lymphocytes / immunology
Lymphocytes / virology
Molecular Targeted Therapy / methods
Pandemics
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / immunology
Pneumonia, Viral / virology
SARS-CoV-2
Severity of Illness Index
Signal Transduction

Substances

Antibodies, Monoclonal
Antiviral Agents
Cytokines
Complement C5a